Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cadonilimab Plus Chemotherapy in Resectable PD-L1 Negative NSCLC
NCT06532591Phase 2Recruiting
- Sponsor
- Sichuan Cancer Hospital
- Start
- Aug 2024
- Primary completion
- Apr 2025
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of cadonilimab in non-small cell lung cancer (NSCLC), sponsored by Sichuan Cancer Hospital. Started Aug 2024; status: recruiting.
02
Drugs
cadonilimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06532591.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06532591.